AstraZeneca has decided to stop a mid-stage trial for the asthma medication elarekibep after data from a non-clinical toxicology study revealed inflammation-related lung tissue damage, according to an announcement Wednesday by Pieris Pharmaceuticals Inc., which licensed the inhaled IL-4 receptor alpha inhibitor to the British pharma.